Streptococcus Salivarius K12
An oral probiotic that colonises the throat and produces bacteriocins against Streptococcus pyogenes. Several trials report fewer sore throat and ear infection episodes, but almost all are small and poorly blinded.
Evidence last reviewed: August 2026
What the science says
- Possible reduction in sore throat episodes Limited evidence
A systematic review of K12 for treating or preventing sore throat found studies suggesting reduced episodes of streptococcal pharyngitis, while judging the trials small, largely non-blinded and at substantial risk of bias. The reviewers concluded that better trials are needed before recommending it.
- Ear and oral cavity outcomes Limited evidence
A systematic review of K12 in ear and oral health reported reductions in recurrent pharyngotonsillitis and acute otitis media across the available studies, again with methodological weaknesses throughout.
- Paediatric prevention study Limited evidence
An open-label study in three-year-old children reported fewer episodes of streptococcal pharyngotonsillitis, scarlet fever and acute otitis media over a 90-day treatment plus follow-up. The lack of blinding and placebo control limits what can be concluded.
Dosage & safety
Scientific references
- Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review
- Influence of Oral Probiotic Streptococcus salivarius K12 on Ear and Oral Cavity Health in Humans: Systematic Review
- Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Immunity
- Vitamin C Limited evidence
- Zinc Moderate evidence
- Elderberry Limited evidence
- L-Lysine Limited evidence
- Echinacea Limited evidence
- Andrographis Moderate evidence